KYMR
USDKymera Therapeutics Inc. Common Stock
Prix en Temps Réel
Graphique des Prix
Métriques Clés
Métriques de Marché
Ouverture
$55.800
Haut
$61.580
Bas
$55.660
Volume
0.77M
Fondamentaux de l'Entreprise
Capitalisation Boursière
4.3B
Industrie
Biotechnologie
Pays
United States
Statistiques de Trading
Volume Moyen
0.75M
Bourse
NGM
Devise
USD
Intervalle sur 52 Semaines
Actualités Connexes
Guggenheim Assumes Kymera Therapeutics at Buy, Announces Price Target of $90
Guggenheim analyst Brad Canino assumes Kymera Therapeutics with a Buy rating and announces Price Target of $90.
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically
BTIG Maintains Buy on Kymera Therapeutics, Raises Price Target to $75
BTIG analyst Jeet Mukherjee maintains Kymera Therapeutics with a Buy and raises the price target from $59 to $75.
Mizuho Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $81
Mizuho analyst Joseph Catanzaro initiates coverage on Kymera Therapeutics with a Outperform rating and announces Price Target of $81.
Actions Connexes
NERV
Minerva Neurosciences Inc
TKO
TKO Group Holdings Inc.
ESOA
Energy Services of America Corporation
PCK
Pimco California Municipal Income Fund II Common Shares of Beneficial Interest
UI
Ubiquiti Inc.
Restez Informé
Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.